Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -10.85% is 67% above its 5-year average of -33.02%, near the high end of its 5-year range (-72.85%–0.14%).
24.18% above its 12-month average of -14.31%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -9.58%.
NET PROFIT MARGIN
-10.85%
NET PROFIT MARGIN AVG TTM
-14.31%
NET PROFIT MARGIN AVG 3Y
-20.63%
NET PROFIT MARGIN AVG 5Y
-33.02%
NET PROFIT MARGIN AVG 10Y
-21.68%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+24.18%
CURRENT VS 3Y AVG
+47.40%
CURRENT VS 5Y AVG
+67.14%
CURRENT VS 10Y AVG
+49.96%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 627 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Evolus, Inc.
Market Cap
$480.15M
Net Profit Margin
-10.85%
TTM Avg
-14.31%
3Y Avg
-20.63%
5Y Avg
-33.02%
Market Cap
$472.24M
Net Profit Margin
2.94%
TTM Avg
-53.14%
3Y Avg
-197.29%
5Y Avg
-267.69%
Market Cap
$469.98M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$469.55M
Net Profit Margin
-3.06%
TTM Avg
-9.59%
3Y Avg
-17.39%
5Y Avg
-29.37%
Market Cap
$494.52M
Net Profit Margin
-32724.20%
TTM Avg
-6251.97%
3Y Avg
-3125.99%
5Y Avg
-2083.99%
Market Cap
$466.40M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
11.36%
5Y Avg
9.09%
Market Cap
$496.99M
Net Profit Margin
-3566.68%
TTM Avg
-585431.82%
3Y Avg
-433391.80%
5Y Avg
-288954.46%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $480.15M | -10.85% | -14.31% | -20.63% | -33.02% |
| Arvinas, Inc. (ARVN)vs › | $472.24M | 2.94% | -53.14% | -197.29% | -267.69% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $469.98M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cerus Corporation (CERS)vs › | $469.55M | -3.06% | -9.59% | -17.39% | -29.37% |
| Oculis Holding AG (OCS)vs › | $494.52M | -32724.20% | -6251.97% | -3125.99% | -2083.99% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $466.40M | 0.00% | 0.00% | 11.36% | 9.09% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $496.99M | -3566.68% | -585431.82% | -433391.80% | -288954.46% |
| NRC Health (NRC)vs › | $461.11M | 4.18% | 12.88% | 16.89% | 20.14% |
| Kamada Ltd. (KMDA)vs › | $455.78M | 11.60% | 10.09% | 6.05% | 5.82% |
| Monopar Therapeutics Inc. (MNPR)vs › | $511.12M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-7.3%
Net Profit Margin
-10.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -9.58% |
| 2026-03-31 | -14.59% |
| 2025-12-31 | 0.14% |
| 2025-09-30 | -22.82% |
| 2025-06-30 | -24.70% |
| 2025-03-31 | -27.57% |
| 2024-12-31 | -8.60% |
| 2024-09-30 | -31.38% |
| 2024-06-30 | -16.96% |
| 2024-03-31 | -22.09% |
| 2023-12-31 | -19.40% |
| 2023-09-30 | -33.83% |
| 2023-06-30 | -36.76% |
| 2023-03-31 | -35.45% |
| 2022-12-31 | -30.16% |
| 2022-09-30 | -59.81% |
| 2022-06-30 | -63.16% |
| 2022-03-31 | -51.61% |
| 2021-12-31 | -52.45% |
| 2021-09-30 | -72.85% |
| 2021-06-30 | -59.78% |
| 2021-03-31 | 52.29% |
| 2020-12-31 | -537.95% |
| 2020-09-30 | -64.88% |
| 2020-06-30 | -270.63% |
| 2020-03-31 | -188.02% |
| 2019-12-31 | -74.60% |
| 2019-09-30 | -204.94% |
| 2019-06-30 | -1625.57% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
